UCSF Selects Filament Health Psilocybin Drug Candidate for Alzheimer’s Preclinical Study
Click to view quick news summary (Spoiler)
The University of California, San Francisco (UCSF) has selected PEX010, Filament Health’s natural botanical psilocybin drug candidate, to evaluate its therapeutic efficacy against early biological indicators of Alzheimer's disease.
The University of California, San Francisco (UCSF) has selected PEX010, a standardized, patented natural psilocybin drug candidate developed by Filament Health, for a new study investigating preclinical markers of Alzheimer’s disease. Red Light Holland confirmed the selection of the drug, which currently serves as a research material in more than 80 clinical and preclinical studies worldwide.
Researchers at UCSF will utilize the PEX010 compound to examine its potential impact on biological indicators associated with the early stages of Alzheimer’s. Filament Health manufactures the drug as a standardized botanical psilocybin, a process that ensures consistency in dosing and chemical composition for scientific trials. This selection follows the drug’s widespread adoption in the global research community, where it has already undergone extensive testing across various therapeutic applications.
Dosing & Structural Formats
PEX010 is a patented, standardized botanical psilocybin drug candidate developed by the natural psychedelic pharmaceutical company Filament Health. It is crafted from natural Psilocybe mushrooms using proprietary extraction and stabilization methods, producing pharmaceutical-grade, GMP-compliant doses for use in global clinical trials. Unlike synthetic psilocybin, PEX010 maintains a botanical matrix of natural compounds extracted directly from mushrooms.
It is most commonly distributed in specific oral dosages:
- 25 mg: The standard dose evaluated in major Phase II trials for conditions like treatment-resistant depression, substance use disorders, and palliative care.
- 1 mg: A standardized microdose format.
Clinical Research Applications
PEX010 is authorized for investigation in dozens of clinical trials worldwide, including independent studies by major institutions like Johns Hopkins University, UCSF, and the University of British Columbia.
